News

On June 24, 2017 Romuald Harwas assumed the position of the Financial Director of Nestmedic SA Romuald has a dozen or so years experience in designing and implementing business financial strategies, including companies from the health care industry and companies listed in the Warsaw Stock Exchange (WSE).

Romuald has been specializing in finance since 1997. Over the years of his career, he has been designing and supervising budgets, managed accounting departments, and co-ordinated investment processes, and also analyzed corporate IT needs – mainly in the health care, pharmaceutical and technological sectors. For several years, he lived and worked in Australia. From 2014 he was in the role of Financial Director at Synektik SA, a major WSE company dealing with image diagnostics and nuclear medicine.

– In my experience, I have combined supervising the finances of technological and industrial companies with managing strategic corporate departments form health care and pharmaceutical sectors, which will help me pro-actively and successfully join the effort of building and implementing Nestmedic’s strategy. The sector in which the company operates is well-known to me. I know the potential of Nestmedic and how to use this strength to establish the Pregnabit system position, says Romuald.

In our company, Romuald will be responsible for designing and implementing our financial strategy, supervising the budget, preparing reports and maintaining relationships with the capital market. Additionally, he will be responsible for nurturing relationships with investors and building investment plans for the company.

A short footage from the IPO

We are proud to announce that on June 12 Nestmedic goes public on NewConnect. After the first issuance of stocks in the first quarter, the company obtained over PLN 8.4m from individual investors and investment funds.

The IPO is scheduled for 11:15 AM June 12, in the Warsaw Stock Exchange Listing Hall at 4 Książęca Street, Warsaw.

– Entering the NewConnect market will enable us to develop faster, which will undoubtedly add to the growth of the company equity. Being listed on the small and then on the main market of the Warsaw Stock Exchange, the company becomes entirely transparent for investors and clients, which in turn translates into a greater confidence in doing business. This is extremely important for us now that we are starting with selling the Pregnabit system in Poland and looking for investors abroad, says Patrycja Wizińska-Socha, MD PhD, a co-founder and the CEO of Nestmedic.

We are going to start selling Pregnabit in September. The company is currently building a network of sales representatives across the country and is involved in advanced talks with resellers from abroad. The company has just accomplished a GoGlobal project where along with Fraunhofer Institute we carried out an analysis of the German market and started talks on co-operation with German companies. Nestmedic is not going to stop at Poland’s neighboring countries.

– We are researching many markets and analyzing their potential. Nestmedic has been meant to go global since the very beginning, therefore now we are looking for an optimal expansion path towards international markets. We are observing a great interest in our product, so we are soon going to announce information on the first agreements, adds Patrycja Wizińska-Socha.

Nestmedic is just closing an intensive stage of beta-testing, which has been going on since the beginning of this year and enabled us to collect feedback on the performance of the Pregnabit system from pregnant women, physicians and midwives.

– The beta-tests have turned out to be successful for us. The system has proven successful in supporting pregnant women and clinicians in their day-to-day work – we have received a lot of positive feedback and constructive remarks which can help us customize the product to meet the needs and expectations in order to make the care for women in their last trimester be at the top level, says Anna Skotny, MD PhD, R&D Director and a co-founder of Nestmedic.